p16INK4a Recombinant Antibody / CDKN2A

p16INK4a Recombinant Antibody / CDKN2A

• Description: p16INK4a/CDKN2A is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.
• CAS Number: 9000-83-3
• UniProt: P42771
• Host: Mouse
• Immunogen: Purified recombinant prokaryotic full-length human protein was used as the immunogen for the CDKN2A antibody.
• Clonality: Monoclonal
• Isotype: IgG1 κ
• Type: Recombinant
• Applications: IHC-P
• Format: Purified
• Buffer: 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
• Reconstitution: Aliquot the CDKN2A antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
• Limitations: This CDKN2A antibody is available for research use only.